Literature DB >> 27326758

Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.

W Cliff Rutter1,2, Donna R Burgess1,2, David S Burgess1.   

Abstract

Pseudomonas aeruginosa and Staphylococcus aureus are common pathogens in cystic fibrosis (CF) patients with increasing multidrug resistance (MDR). This study characterized antimicrobial susceptibility trends among organisms isolated from the respiratory tract of CF patients. Microbiological culture and sensitivity results for all CF patients were collected from January 2010 through December 2014. Minimum inhibitory concentrations were obtained using Phoenix® and Etest® methods. Clinical and Laboratory Standards Institute guidelines were used to remove duplicate isolates and develop antimicrobial susceptibility reports. MDR was defined as resistance to one agent in three or more antibiotic classes or oxacillin resistance in S. aureus. Overall, 542 bacterial isolates from 376 cultures were analyzed for trends. P. aeruginosa (41%), S. aureus (40%), and Stenotrophomonas maltophilia (8%) were the most commonly isolated organisms. Multidrug-resistant organism isolation increased from 39% to 49% (r = 0.76, p = 0.13), while representing 47.6% of all isolates. Multidrug-resistant P. aeruginosa incidence increased each year from 26% to 43% (r = 0.89, p = 0.046), while P. aeruginosa isolation decreased from 47% to 38% over the study period (r = -0.93, p = 0.02). MRSA accounted for 62.6% of all S. aureus isolated, while overall multidrug-resistant S. aureus incidence was 73.1% in all cultures. MDR among common pathogens in CF continues to increase. Empiric therapy for CF exacerbations should be targeted to previous antimicrobial susceptibility, and P. aeruginosa and S. aureus should be empirically covered.

Entities:  

Keywords:  bacterial resistance; cystic fibrosis; epidemiology; infectious disease

Mesh:

Substances:

Year:  2016        PMID: 27326758     DOI: 10.1089/mdr.2016.0048

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  20 in total

1.  Stenotrophomonas maltophilia Encodes a VirB/VirD4 Type IV Secretion System That Modulates Apoptosis in Human Cells and Promotes Competition against Heterologous Bacteria, Including Pseudomonas aeruginosa.

Authors:  Megan Y Nas; Richard C White; Ashley L DuMont; Alberto E Lopez; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

2.  Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis.

Authors:  Mila M Almeida; Meyvianne T Freitas; Tania W Folescu; Monica C Firmida; Ana Paula D'A Carvalho-Assef; Elizabeth A Marques; Robson S Leão
Journal:  Curr Microbiol       Date:  2021-01-06       Impact factor: 2.188

3.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

4.  High Rates of Extensively Drug-Resistant Pseudomonas aeruginosa in Children with Cystic Fibrosis.

Authors:  Juan C Gutiérrez-Santana; Armando Gerónimo-Gallegos; Mónica B Martínez-Corona; Marisol López-López; Julia D Toscano-Garibay; Francisco Cuevas-Schacht; Victor R Coria-Jiménez
Journal:  Curr Microbiol       Date:  2022-10-08       Impact factor: 2.343

Review 5.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

6.  Genotypic and Phenotypic Characterization of Stenotrophomonas maltophilia Strains from a Pediatric Tertiary Care Hospital in Serbia.

Authors:  Haowa Madi; Jovanka Lukić; Zorica Vasiljević; Marjan Biočanin; Milan Kojić; Branko Jovčić; Jelena Lozo
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

Review 7.  Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease.

Authors:  Camilla Margaroli; Rabindra Tirouvanziam
Journal:  Mol Cell Pediatr       Date:  2016-12-05

8.  The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against Pseudomonas aeruginosa in Conditions Mimicking Cystic Fibrosis Sputum.

Authors:  Giuseppantonio Maisetta; Lucia Grassi; Semih Esin; Ilaria Serra; Mariano A Scorciapino; Andrea C Rinaldi; Giovanna Batoni
Journal:  Int J Mol Sci       Date:  2017-09-16       Impact factor: 5.923

9.  Let-7b-5p in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity of P. aeruginosa.

Authors:  Katja Koeppen; Amanda Nymon; Roxanna Barnaby; Laura Bashor; Zhongyou Li; Thomas H Hampton; Amanda E Liefeld; Fred W Kolling; Ian S LaCroix; Scott A Gerber; Deborah A Hogan; Swetha Kasetty; Carey D Nadell; Bruce A Stanton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

Review 10.  Personalized or Precision Medicine? The Example of Cystic Fibrosis.

Authors:  Fernando A L Marson; Carmen S Bertuzzo; José D Ribeiro
Journal:  Front Pharmacol       Date:  2017-06-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.